Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Prompt aflibercept
Regeneron UK Limited
Diabetic Retinopathy
1 trial -
QL2107, PEMBROLIZUMAB
Lacuna Pharma Pty Ltd
Non-small cell lung cancer
1 trial -
Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)
AstraZeneca
Bipolar Disorder
1 trial -
RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/ml Injektionslösung, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/mL solución inyectable, Radelumin 2000 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, Radelumin 1300 MBq/ml Injektionslösung, Radelumin 1300 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 1300 MBq/mL solución inyect
Advanced Accelerator Applications
Prostate Cancer
1 trial -
RAMUCIRUMAB, ERLOTINIB
Eli Lilly Co.
Metastatic Non-Small Cell Lung Cancer
1 trial -
RAPIBLOC 300 mg, poudre pour solution pour perfusion
Pari Pharma GmbH
Patients with microcirculatory abnormalities during septic shock
1 trial -
REGN4461 - Mibavademab
Lacuna Pharma Pty Ltd
Monogenic obesity
1 trial -
REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508
Lacuna Pharma Pty Ltd
Thromboembolic disease
1 trial -
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
RedHill Biopharma
Crohn Disease
1 trial -
RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE
Takeda
Active Chronic Pouchitis
1 trial -
RILUTEK 50 mg film-coated tablets, masitinib, Placebo to 200mg masitinib, masitinib, Riluzole Zentiva 50 mg film-coated tablets, Placebo to 100mg masitinib
AB Science
Amyotrophic Lateral Sclerosis
1 trial -
RITUXIMAB , SODIUM CHLORIDE, Placebo for lenalidomide 25mg, PREDNISONE , MINJUVI 200 mg powder for concentrate for solution for infusion, PREDNISOLONE , LENALIDOMIDE, DOXORUBICIN , Placebo for lenalidomide 10mg, VINCRISTINE , LENALIDOMIDE, Placebo for lenalidomide 15mg, LENALIDOMIDE, CYCLOPHOSPHAMIDE
Incyte
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)
1 trial -
RITUXIMAB, Capsule, hard, Calquence 100 mg hard capsules, BENDAMUSTINE
Lacuna Pharma Pty Ltd
Mantle Cell Lymphoma
1 trial -
RITUXIMAB, LENALIDOMIDE , RITUXIMAB, RITUXIMAB, RITUXIMAB
Fondazione Telethon ETS
Follicular lymphoma
1 trial -
RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets
Pari Pharma GmbH
Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.
1 trial -
RITUXIMAB, PLERIXAFOR, OTL-103, FLUDARABINE PHOSPHATE, LENOGRASTIM, BUSULFAN
Fondazione Telethon ETS
Wiskott-Aldrich Syndrome
1 trial -
RO5541267
Hoffmann-La Roche
Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Extensive-stage small-cell lung carcinoma (ES-SCLC) • Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: • Resected Stage IIB-IIIB (early-stage; per the UICC/AJCC staging system, 8th edition) non-small cell lung carcinoma (NSCLC)
1 trial -
RO7046015, Placebo Prasinezumab
Hoffmann-La Roche
Early-Stage Parkinson’s Disease (PD)
1 trial -
RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D
Hoffmann-La Roche
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer
1 trial -
RO7795068, RO7795068, RO7795068 Placebo, RO7795068, RO7795068, RO7795068, RO7795068
Hoffmann-La Roche
Obesity or Overweight and Type 2 Diabetes
1 trial -
RO7795068, RO7795068, RO7795068, RO7795068, RO7795068, RO7795068 Placebo, RO7795068
Hoffmann-La Roche
Obesity or Overweight Without Type 2 Diabetes
1 trial -
Rabies Vaccine (Serum-free Vero Cell), Freeze-dried
Sinovac Research and Development Co.,
Rabies
2 trials -
Rabies vaccine
Sinovac Research and Development Co.,
Rabies (Healthy Volunteers)
1 trial -
Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)
The George Institute
Rabies
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources